

**Chapter 07**  
**References**

## 7 References

1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. *Cell*. 2011;144(5):646-674.
2. Sanderson SC, Waller J, Jarvis MJ, Humphries SE, Wardle J. Awareness of lifestyle risk factors for cancer and heart disease among adults in the UK. *Patient Education and Counseling*. 2009;74(2):221-227.
3. Alberts B, Johnson A, Lewis J, et al. . *Molecular Biology of the Cell*. New York: Garland Science; 2002.
4. van der Lee R, Buljan M, Lang B, Weatheritt RJ, Daughdrill GW, Dunker AK, Fuxreiter M, Gough J, Gsponer J, Jones DT, Kim PM, Kriwacki RW, Oldfield CJ, Pappu RV, Tompa P, Uversky VN, Wright PE, Babu MM. Classification of intrinsically disordered regions and proteins. *Chemical reviews*. 2014;114(13):6589-6631.
5. Barberis M, Klipp E, Vanoni M, Alberghina L. Cell size at S phase initiation: an emergent property of the G1/S network. *PLoS computational biology*. 2007;3(4):e64.
6. Deshpand R, Chandra M, Rauthan A. Evolving trends in lung cancer: Epidemiology, diagnosis, and management. *Indian journal of cancer*. 2022;59(Supplement):S90-s105.
7. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA: a cancer journal for clinicians*. 2021;71(3):209-249.
8. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. *CA: a cancer journal for clinicians*. 2023;73(1):17-48.
9. Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. *International journal of cancer*. 2021.
10. Mathur P, Sathishkumar K, Chaturvedi M, Das P, Sudarshan KL, Santhappan S, Nallasamy V, John A, Narasimhan S, Roselind FS. Cancer Statistics, 2020: Report From National Cancer Registry Programme, India. *JCO global oncology*. 2020;6:1063-1075.
11. Parsa N. Environmental factors inducing human cancers. *Iranian journal of public health*. 2012;41(11):1-9.
12. Lee EY, Muller WJ. Oncogenes and tumor suppressor genes. *Cold Spring Harbor perspectives in biology*. 2010;2(10):a003236.
13. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. *Genes & development*. 2012;26(12):1268-1286.
14. Krump NA, You J. Molecular mechanisms of viral oncogenesis in humans. *Nature reviews Microbiology*. 2018;16(11):684-698.
15. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, Sharma S, Dubinett SM. Smoking and lung cancer: the role of inflammation. *Proceedings of the American Thoracic Society*. 2008;5(8):811-815.
16. Larsen JE, Minna JD. Molecular biology of lung cancer: clinical implications. *Clinics in chest medicine*. 2011;32(4):703-740.
17. Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. *Clinics in chest medicine*. 2011;32(4):605-644.
18. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. *Nature reviews Cancer*. 2014;14(8):535-546.

19. Šileikienė V, Gurskytė V, Zeleckienė I, Bernotienė E, Čibiras S. Pulmonary artery coil embolisation prevented tumour progression in a patient with advanced squamous cell lung carcinoma. *Upsala journal of medical sciences*. 2020;125(3):257-261.
20. Riaz SP, Lüchtenborg M, Coupland VH, Spicer J, Peake MD, Møller H. Trends in incidence of small cell lung cancer and all lung cancer. *Lung cancer (Amsterdam, Netherlands)*. 2012;75(3):280-284.
21. Zappa C, Mousa SA. Non-small cell lung cancer: current treatment and future advances. *Translational lung cancer research*. 2016;5(3):288-300.
22. Miziak P, Baran M, Błaszczak E, Przybyszewska-Podstawka A, Kałafut J, Smok-Kalwat J, Dmoszyńska-Graniczka M, Kiełbus M, Stepulak A. Estrogen Receptor Signaling in Breast Cancer. *Cancers*. 2023;15(19).
23. Baskar R, Lee KA, Yeo R, Yeoh KW. Cancer and radiation therapy: current advances and future directions. *International journal of medical sciences*. 2012;9(3):193-199.
24. Bukowski K, Kciuk M, Kontek R. Mechanisms of Multidrug Resistance in Cancer Chemotherapy. *International journal of molecular sciences*. 2020;21(9).
25. Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. *European journal of pharmacology*. 2014;740:364-378.
26. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. *Frontiers in molecular biosciences*. 2020;7:193.
27. Farjadian F, Ghasemi A, Gohari O, Roointan A, Karimi M, Hamblin MR. Nanopharmaceuticals and nanomedicines currently on the market: challenges and opportunities. *Nanomedicine (London, England)*. 2019;14(1):93-126.
28. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. *Nature Reviews Drug Discovery*. 2021;20(2):101-124.
29. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MdP, Acosta-Torres LS, Diaz-Torres LA, Grillo R, Swamy MK, Sharma S, Habtemariam S, Shin H-S. Nano based drug delivery systems: recent developments and future prospects. *Journal of Nanobiotechnology*. 2018;16(1):71.
30. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. *International journal of nanomedicine*. 2008;3(2):133-149.
31. Yu B, Tai HC, Xue W, Lee LJ, Lee RJ. Receptor-targeted nanocarriers for therapeutic delivery to cancer. *Molecular membrane biology*. 2010;27(7):286-298.
32. Karimi M, Bahrami S, Ravari SB, Zangabad PS, Mirshekari H, Bozorgomid M, Shahreza S, Sori M, Hamblin MR. Albumin nanostructures as advanced drug delivery systems. *Expert opinion on drug delivery*. 2016;13(11):1609-1623.
33. Azimi B, Nourpanah P, Rabiee M, Arbab S. Producing gelatin nanoparticles as delivery system for bovine serum albumin. *Iranian biomedical journal*. 2014;18(1):34-40.
34. Hong S, Choi DW, Kim HN, Park CG, Lee W, Park HH. Protein-Based Nanoparticles as Drug Delivery Systems. *Pharmaceutics*. 2020;12(7).
35. Kianfar E. Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles. *Journal of Nanobiotechnology*. 2021;19(1):159.
36. Larsen MT, Kuhlmann M, Hvam ML, Howard KA. Albumin-based drug delivery: harnessing nature to cure disease. *Molecular and cellular therapies*. 2016;4:3.
37. Spada A, Emami J, Tuszyński JA, Lavasanifar A. The Uniqueness of Albumin as a Carrier in Nanodrug Delivery. *Molecular Pharmaceutics*. 2021;18(5):1862-1894.
38. Zhang Y, Guo Z, Cao Z, Zhou W, Zhang Y, Chen Q, Lu Y, Chen X, Guo Q, Li C, Liang D, Sun T, Jiang C. Endogenous albumin-mediated delivery of redox-responsive

- paclitaxel-loaded micelles for targeted cancer therapy. *Biomaterials*. 2018;183:243-257.
39. Huang M, Lu JJ, Ding J. Natural Products in Cancer Therapy: Past, Present and Future. *Natural products and bioprospecting*. 2021;11(1):5-13.
  40. Masyita A, Mustika Sari R, Dwi Astuti A, Yasir B, Rahma Rumata N, Emran TB, Nainu F, Simal-Gandara J. Terpenes and terpenoids as main bioactive compounds of essential oils, their roles in human health and potential application as natural food preservatives. *Food chemistry: X*. 2022;13:100217.
  41. Majhi S, Das D. Chemical derivatization of natural products: Semisynthesis and pharmacological aspects- A decade update. *Tetrahedron*. 2021;78:131801.
  42. Yao H, Liu J, Xu S, Zhu Z, Xu J. The structural modification of natural products for novel drug discovery. *Expert Opinion on Drug Discovery*. 2017;12(2):121-140.
  43. Vitaku E, Smith DT, Njardarson JTJomc. Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among US FDA approved pharmaceuticals: miniperspective. 2014;57(24):10257-10274.
  44. Franklin ECJCR. Heterocyclic Nitrogen Compounds. I. Pentacyclic Compounds. 1935;16(3):305-361.
  45. Dheer D, Singh V, Shankar R. Medicinal attributes of 1,2,3-triazoles: Current developments. *Bioorganic Chemistry*. 2017;71:30-54.
  46. Stefely JA, Palchaudhuri R, Miller PA, Peterson RJ, Moraski GC, Hergenrother PJ, Miller MJ. N-((1-benzyl-1H-1,2,3-triazol-4-yl)methyl)arylamide as a new scaffold that provides rapid access to antimicrotubule agents: synthesis and evaluation of antiproliferative activity against select cancer cell lines. *Journal of medicinal chemistry*. 2010;53(8):3389-3395.
  47. Ashwini N, Garg M, Mohan CD, Fuchs JE, Rangappa S, Anusha S, Swaroop TR, Rakesh KS, Kanojia D, Madan V, Bender A, Koeffler HP, Basappa, Rangappa KS. Synthesis of 1,2-benzisoxazole tethered 1,2,3-triazoles that exhibit anticancer activity in acute myeloid leukemia cell lines by inhibiting histone deacetylases, and inducing p21 and tubulin acetylation. *Bioorganic & Medicinal Chemistry*. 2015;23(18):6157-6165.
  48. Majeed R, Sangwan PL, Chinthakindi PK, Khan I, Dangroo NA, Thota N, Hamid A, Sharma PR, Saxena AK, Koul SJEjmc. Synthesis of 3-O-propargylated betulonic acid and its 1, 2, 3-triazoles as potential apoptotic agents. 2013;63:782-792.
  49. Khaybullin RN, Zhang M, Fu J, Liang X, Li T, Katritzky AR, Okunieff P, Qi XJM. Design and synthesis of isosteviol triazole conjugates for cancer therapy. 2014;19(11):18676-18689.
  50. Aneja B, Azam M, Alam S, Perwez A, Maguire R, Yadava U, Kavanagh K, Daniliuc CG, Rizvi MMA, Haq QMRJAo. Natural product-based 1, 2, 3-triazole/sulfonate analogues as potential chemotherapeutic agents for bacterial infections. 2018;3(6):6912-6930.
  51. Zhang X, Zhang S, Zhao S, Wang X, Liu B, Xu H. Click Chemistry in Natural Product Modification. *Frontiers in chemistry*. 2021;9:774977.
  52. Dias DA, Urban S, Roessner U. A historical overview of natural products in drug discovery. *Metabolites*. 2012;2(2):303-336.
  53. Zielińska-Błajet M, Feder-Kubis J. Monoterpenes and Their Derivatives-Recent Development in Biological and Medical Applications. *International journal of molecular sciences*. 2020;21(19).
  54. Lengerli D, Ibis K, Nural Y, Banoglu E. The 1,2,3-triazole 'all-in-one' ring system in drug discovery: a good bioisostere, a good pharmacophore, a good linker, and a versatile synthetic tool. *Expert Opin Drug Discov*. 2022;17(11):1209-1236.

55. Ganesan A. The impact of natural products upon modern drug discovery. *Current opinion in chemical biology*. 2008;12(3):306-317.
56. Beutler JA. Natural Products as a Foundation for Drug Discovery. *Current protocols in pharmacology*. 2009;46:9.11.11-19.11.21.
57. Atanasov AG, Zotchev SB, Dirsch VM, Orhan IE, Banach M, Rollinger JM, Barreca D, Weckwerth W, Bauer R, Bayer EA, Majeed M, Bishayee A, Bochkov V, Bonn GK, Braidy N, Bucar F, Cifuentes A, D'Onofrio G, Bodkin M, Diederich M, Dinkova-Kostova AT, Efferth T, El Bairi K, Arkells N, Fan T-P, Fiebich BL, Freissmuth M, Georgiev MI, Gibbons S, Godfrey KM, Gruber CW, Heer J, Huber LA, Ibanez E, Kijjoo A, Kiss AK, Lu A, Macias FA, Miller MJS, Mocan A, Müller R, Nicoletti F, Perry G, Pittalà V, Rastrelli L, Ristow M, Russo GL, Silva AS, Schuster D, Sheridan H, Skalicka-Woźniak K, Skaltsounis L, Sobarzo-Sánchez E, Brecht DS, Stuppner H, Sureda A, Tzvetkov NT, Vacca RA, Aggarwal BB, Battino M, Giampieri F, Wink M, Wolfender J-L, Xiao J, Yeung AWK, Lizard G, Popp MA, Heinrich M, Berindan-Neagoe I, Stadler M, Daglia M, Verpoorte R, Supuran CT, the International Natural Product Sciences T. Natural products in drug discovery: advances and opportunities. *Nature Reviews Drug Discovery*. 2021;20(3):200-216.
58. Najmi A, Javed SA, Al Bratty M, Alhazmi HA. Modern Approaches in the Discovery and Development of Plant-Based Natural Products and Their Analogues as Potential Therapeutic Agents. *Molecules (Basel, Switzerland)*. 2022;27(2).
59. Zhu Y, Ouyang Z, Du H, Wang M, Wang J, Sun H, Kong L, Xu Q, Ma H, Sun Y. New opportunities and challenges of natural products research: When target identification meets single-cell multiomics. *Acta Pharmaceutica Sinica B*. 2022;12(11):4011-4039.
60. Guo Z. The modification of natural products for medical use. *Acta Pharmaceutica Sinica B*. 2017;7(2):119-136.
61. Newman DJ, Cragg GM. Natural Products as Sources of New Drugs from 1981 to 2014. *Journal of natural products*. 2016;79(3):629-661.
62. Atanasov AG, Waltenberger B, Pferschy-Wenzig E-M, Linder T, Wawrosch C, Uhrin P, Temml V, Wang L, Schwaiger S, Heiss EH, Rollinger JM, Schuster D, Breuss JM, Bochkov V, Mihovilovic MD, Kopp B, Bauer R, Dirsch VM, Stuppner H. Discovery and resupply of pharmacologically active plant-derived natural products: A review. *Biotechnology Advances*. 2015;33(8):1582-1614.
63. Tewary P, Gunatilaka AL, Sayers TJJCI, Immunotherapy. Using natural products to promote caspase-8-dependent cancer cell death. 2017;66:223-231.
64. Bilia AR, Piazzini V, Guccione C, Risaliti L, Asprea M, Capecchi G, Bergonzi MCJPM. Improving on nature: the role of nanomedicine in the development of clinical natural drugs. 2017;83(05):366-381.
65. Nagaich U. Natural products-based nanomedicine. *Journal of advanced pharmaceutical technology & research*. 2018;9(4):119.
66. Fai YM, Tao CCJNPM. A review of presence of oleanolic acid in natural products. 2009;2:77-290.
67. Guinda Á, Pérez-Camino MC, Lanzón AJEjols, technology. Supplementation of oils with oleanolic acid from the olive leaf (*Olea europaea*). 2004;106(1):22-26.
68. Pollier J, Goossens A. Oleanolic acid. *Phytochemistry*. 2012;77:10-15.
69. Heinzen H, de Vries JX, Moyna P, Remberg G, Martinez R, Tietze LFJPA. Mass spectrometry of labelled triterpenoids: thermospray and electron impact ionization analysis. 1996;7(5):237-244.
70. Wang X, Ye XL, Liu R, Chen HL, Bai H, Liang X, Zhang XD, Wang Z, Li WL, Hai CX. Antioxidant activities of oleanolic acid in vitro: possible role of Nrf2 and MAP kinases. *Chemico-biological interactions*. 2010;184(3):328-337.

71. Wang X, Liu R, Zhang W, Zhang X, Liao N, Wang Z, Li W, Qin X, Hai C. Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects. *Molecular and cellular endocrinology*. 2013;376(1-2):70-80.
72. Jesus JA, Lago JH, Laurenti MD, Yamamoto ES, Passero LF. Antimicrobial activity of oleanolic and ursolic acids: an update. *Evidence-based complementary and alternative medicine : eCAM*. 2015;2015:620472.
73. Yoo SR, Jeong SJ, Lee NR, Shin HK, Seo CS. Quantification Analysis and In Vitro Anti-Inflammatory Effects of 20-Hydroxyecdysone, Momordin Ic, and Oleanolic Acid from the Fructus of *Kochia scoparia*. *Pharmacognosy magazine*. 2017;13(51):339-344.
74. Janicsák G, Veres K, Kakasy AZ, Máthé IJBs, ecology. Study of the oleanolic and ursolic acid contents of some species of the Lamiaceae. 2006;34(5):392-396.
75. Córdova C, Gutiérrez B, Martínez-García C, Martín R, Gallego-Muñoz P, Hernández M, Nieto ML. Oleanolic acid controls allergic and inflammatory responses in experimental allergic conjunctivitis. *PloS one*. 2014;9(4):e91282.
76. Jäger S, Trojan H, Kopp T, Laszczyk MN, Scheffler A. Pentacyclic triterpene distribution in various plants - rich sources for a new group of multi-potent plant extracts. *Molecules (Basel, Switzerland)*. 2009;14(6):2016-2031.
77. Vyas N, Argal AJA PCR. Isolation and characterization of oleanolic acid from roots of *Lantana camara*. 2014;7(Suppl 2):189-191.
78. Xia EQ, Wang BW, Xu XR, Zhu L, Song Y, Li HB. Microwave-assisted extraction of oleanolic acid and ursolic acid from *Ligustrum lucidum* Ait. *International journal of molecular sciences*. 2011;12(8):5319-5329.
79. Misra LN, Dixit AK, Sharma RP. High concentration of hepatoprotective oleanolic acid and its derivatives in *Lantana camara* roots. *Planta medica*. 1997;63(6):582.
80. Wang X, Bai H, Zhang X, Liu J, Cao P, Liao N, Zhang W, Wang Z, Hai C. Inhibitory effect of oleanolic acid on hepatocellular carcinoma via ERK-p53-mediated cell cycle arrest and mitochondrial-dependent apoptosis. *Carcinogenesis*. 2013;34(6):1323-1330.
81. Liese J, Abhari BA, Fulda S. Smac mimetic and oleanolic acid synergize to induce cell death in human hepatocellular carcinoma cells. *Cancer letters*. 2015;365(1):47-56.
82. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. *Nature reviews Drug discovery*. 2012;11(2):109-124.
83. Amara S, Zheng M, Tiriveedhi V. Oleanolic Acid Inhibits High Salt-Induced Exaggeration of Warburg-like Metabolism in Breast Cancer Cells. *Cell biochemistry and biophysics*. 2016;74(3):427-434.
84. Mu DW, Guo HQ, Zhou GB, Li JY, Su B. Oleanolic acid suppresses the proliferation of human bladder cancer by Akt/mTOR/S6K and ERK1/2 signaling. *International journal of clinical and experimental pathology*. 2015;8(11):13864-13870.
85. Wang B, Wang H, Yang Z. MiR-122 inhibits cell proliferation and tumorigenesis of breast cancer by targeting IGF1R. *PloS one*. 2012;7(10):e47053.
86. Zeisel MB, Pfeffer S, Baumert TF. miR-122 acts as a tumor suppressor in hepatocarcinogenesis in vivo. *Journal of hepatology*. 2013;58(4):821-823.
87. Zhao X, Liu M, Li D. Oleanolic acid suppresses the proliferation of lung carcinoma cells by miR-122/Cyclin G1/MEF2D axis. *Molecular and cellular biochemistry*. 2015;400(1-2):1-7.
88. Xi J, Chang Q, Chan CK, Meng ZY, Wang GN, Sun JB, Wang YT, Tong HH, Zheng Y. Formulation development and bioavailability evaluation of a self-nanoemulsified drug delivery system of oleanolic acid. *AAPS PharmSciTech*. 2009;10(1):172-182.
89. Gohil KJ, Patel JA, Gajjar AK. Pharmacological Review on *Centella asiatica*: A Potential Herbal Cure-all. *Indian journal of pharmaceutical sciences*. 2010;72(5):546-556.

90. Mushtaq Z, Imran M, Hussain M, Saeed F, Imran A, Umar M, A. Abdelgawad M, El-Ghorab AH, Ahmed A, Alsagaby SA, Mahomoodally MF, Al Jbawi E. Asiatic acid: a review on its polypharmacological properties and therapeutic potential against various Maladies. *International Journal of Food Properties*. 2023;26(1):1244-1263.
91. Misra LN, Ahmad A. Triterpenoids from *Shorea robusta* resin. *Phytochemistry*. 1997;45(3):575-578.
92. Bharitkar YP, Banerjee M, Kumar S, Paira R, Meda R, Kuotsu K, Mondal NB. Search for a potent microbicidal spermicide from the isolates of *Shorea robusta* resin. *Contraception*. 2013;88(1):133-140.
93. Lv J, Sharma A, Zhang T, Wu Y, Ding X. Pharmacological Review on Asiatic Acid and Its Derivatives: A Potential Compound. *SLAS technology*. 2018;23(2):111-127.
94. Kavitha CV, Jain AK, Agarwal C, Pierce A, Keating A, Huber KM, Serkova NJ, Wempe MF, Agarwal R, Deep G. Asiatic acid induces endoplasmic reticulum stress and apoptotic death in glioblastoma multiforme cells both in vitro and in vivo. *Molecular carcinogenesis*. 2015;54(11):1417-1429.
95. Chen JY, Chen JY, Xu QW, Xu H, Huang ZH. Asiatic acid promotes p21(WAF1/CIP1) protein stability through attenuation of NDR1/2 dependent phosphorylation of p21(WAF1/ CIP1) in HepG2 human hepatoma cells. *Asian Pacific journal of cancer prevention : APJCP*. 2014;15(2):963-967.
96. Lee YS, Jin DQ, Kwon EJ, Park SH, Lee ES, Jeong TC, Nam DH, Huh K, Kim JA. Asiatic acid, a triterpene, induces apoptosis through intracellular Ca<sup>2+</sup> release and enhanced expression of p53 in HepG2 human hepatoma cells. *Cancer letters*. 2002;186(1):83-91.
97. Cho CW, Choi DS, Cardone MH, Kim CW, Sinskey AJ, Rha C. Glioblastoma cell death induced by asiatic acid. *Cell biology and toxicology*. 2006;22(6):393-408.
98. Park BC, Bosire KO, Lee ES, Lee YS, Kim JA. Asiatic acid induces apoptosis in SK-MEL-2 human melanoma cells. *Cancer letters*. 2005;218(1):81-90.
99. Tang XL, Yang XY, Jung HJ, Kim SY, Jung SY, Choi DY, Park WC, Park H. Asiatic acid induces colon cancer cell growth inhibition and apoptosis through mitochondrial death cascade. *Biological & pharmaceutical bulletin*. 2009;32(8):1399-1405.
100. Kim KB, Kim K, Bae S, Choi Y, Cha HJ, Kim SY, Lee JH, Jeon SH, Jung HJ, Ahn KJ, An IS, An S. MicroRNA-1290 promotes asiatic acid-induced apoptosis by decreasing BCL2 protein level in A549 non-small cell lung carcinoma cells. *Oncology reports*. 2014;32(3):1029-1036.
101. Park BC, Paek SH, Lee YS, Kim SJ, Lee ES, Choi HG, Yong CS, Kim JA. Inhibitory effects of asiatic acid on 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol 13-acetate-induced tumor promotion in mice. *Biological & pharmaceutical bulletin*. 2007;30(1):176-179.
102. Kavitha CV, Agarwal C, Agarwal R, Deep G. Asiatic acid inhibits pro-angiogenic effects of VEGF and human gliomas in endothelial cell culture models. *PloS one*. 2011;6(8):e22745.
103. Hao Y, Huang J, Ma Y, Chen W, Fan Q, Sun X, Shao M, Cai H. Asiatic acid inhibits proliferation, migration and induces apoptosis by regulating Pcd4 via the PI3K/Akt/mTOR/p70S6K signaling pathway in human colon carcinoma cells. *Oncology letters*. 2018;15(6):8223-8230.
104. Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z. Current approaches of nanomedicines in the market and various stage of clinical translation. *Acta pharmaceutica Sinica B*. 2022;12(7):3028-3048.

105. Wu J. The Enhanced Permeability and Retention (EPR) Effect: The Significance of the Concept and Methods to Enhance Its Application. *Journal of personalized medicine*. 2021;11(8).
106. Bazak R, Hourri M, El Achy S, Kamel S, Refaat T. Cancer active targeting by nanoparticles: a comprehensive review of literature. *Journal of cancer research and clinical oncology*. 2015;141(5):769-784.
107. Yewale C, Baradia D, Vhora I, Misra A. Proteins: emerging carrier for delivery of cancer therapeutics. *Expert opinion on drug delivery*. 2013;10(10):1429-1448.
108. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. *Journal of controlled release : official journal of the Controlled Release Society*. 2008;132(3):171-183.
109. Kouchakzadeh H, Safavi MS, Shojaosadati SA. Chapter Four - Efficient Delivery of Therapeutic Agents by Using Targeted Albumin Nanoparticles. In: Donev R, editor. *Advances in Protein Chemistry and Structural Biology*: Academic Press; 2015. p. 121-143.
110. Jahanban-Esfahlan A, Dastmalchi S, Davaran S. A simple improved desolvation method for the rapid preparation of albumin nanoparticles. *International journal of biological macromolecules*. 2016;91:703-709.
111. Storp B, Engel A, Boeker A, Ploeger M, Langer K. Albumin nanoparticles with predictable size by desolvation procedure. *Journal of microencapsulation*. 2012;29(2):138-146.
112. Demirkurt B, Cakan-Akdogan G, Akdogan Y. Preparation of albumin nanoparticles in water-in-ionic liquid microemulsions. *Journal of Molecular Liquids*. 2019;295:111713.
113. Kovács AN, Varga N, Gombár G, Hornok V, Csapó E. Novel feasibilities for preparation of serum albumin-based core-shell nanoparticles in flow conditions. *Journal of Flow Chemistry*. 2020;10(3):497-505.
114. Abolhassani H, Shojaosadati SA. A comparative and systematic approach to desolvation and self-assembly methods for synthesis of piperine-loaded human serum albumin nanoparticles. *Colloids and surfaces B, Biointerfaces*. 2019;184:110534.
115. Boye JI, Alli I, Ismail AA. Interactions Involved in the Gelation of Bovine Serum Albumin. *Journal of Agricultural and Food Chemistry*. 1996;44(4):996-1004.
116. Vehring R. Pharmaceutical particle engineering via spray drying. *Pharmaceutical research*. 2008;25(5):999-1022.
117. Haggag YA, Faheem AM. Evaluation of nano spray drying as a method for drying and formulation of therapeutic peptides and proteins. *Frontiers in pharmacology*. 2015;6:140.
118. Lee SH, Heng D, Ng WK, Chan H-K, Tan RBH. Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy. *International journal of pharmaceuticals*. 2011;403(1):192-200.
119. Abdel-Mageed HM, Fouad SA, Teaima MH, Abdel-Aty AM, Fahmy AS, Shaker DS, Mohamed SA. Optimization of nano spray drying parameters for production of  $\alpha$ -amylase nanopowder for biotherapeutic applications using factorial design. *Drying Technology*. 2019;37(16):2152-2160.
120. Shrimal P, Jadeja G, Patel S. A review on novel methodologies for drug nanoparticle preparation: Microfluidic approach. *Chemical Engineering Research and Design*. 2020;153:728-756.
121. Zhao S, Wang W, Huang Y, Fu Y, Cheng Y. Paclitaxel loaded human serum albumin nanoparticles stabilized with intermolecular disulfide bonds. *MedChemComm*. 2014;5(11):1658-1663.

122. Sparreboom A, Scripture CD, Trieu V, Williams PJ, De T, Yang A, Beals B, Figg WD, Hawkins M, Desai N. Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol). *Clinical Cancer Research*. 2005;11(11):4136-4143.
123. Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, Noker P, Yao R, Labao E, Hawkins M, Soon-Shiong P. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. *Clinical Cancer Research*. 2006;12(4):1317-1324.
124. Miele E, Spinelli GP, Miele E, Tomao F, Tomao S. Albumin-bound formulation of paclitaxel (Abraxane ABI-007) in the treatment of breast cancer. *International journal of nanomedicine*. 2009;4:99-105.
125. Gupta N, Hatoum H, Dy GK. First line treatment of advanced non-small-cell lung cancer - specific focus on albumin bound paclitaxel. *International journal of nanomedicine*. 2014;9:209-221.
126. Mustachio LM, Roszik J. Current Targeted Therapies for the Fight against Non-Small Cell Lung Cancer. *Pharmaceuticals (Basel, Switzerland)*. 2020;13(11).
127. Wieduwilt MJ, Moasser MM. The epidermal growth factor receptor family: biology driving targeted therapeutics. *Cellular and molecular life sciences : CMLS*. 2008;65(10):1566-1584.
128. Bethune G, Bethune D, Ridgway N, Xu Z. Epidermal growth factor receptor (EGFR) in lung cancer: an overview and update. *Journal of thoracic disease*. 2010;2(1):48-51.
129. Wong SF. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. *Clinical therapeutics*. 2005;27(6):684-694.
130. Tseng SH, Chou MY, Chu IM. Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy. *International journal of nanomedicine*. 2015;10:3663-3685.
131. Cho YS, Yoon TJ, Jang ES, Soo Hong K, Young Lee S, Ran Kim O, Park C, Kim YJ, Yi GC, Chang K. Cetuximab-conjugated magneto-fluorescent silica nanoparticles for in vivo colon cancer targeting and imaging. *Cancer letters*. 2010;299(1):63-71.
132. Kao HW, Lin YY, Chen CC, Chi KH, Tien DC, Hsia CC, Lin WJ, Chen FD, Lin MH, Wang HE. Biological characterization of cetuximab-conjugated gold nanoparticles in a tumor animal model. *Nanotechnology*. 2014;25(29):295102.
133. Maya S, Kumar LG, Sarmiento B, Sanoj Rejinold N, Menon D, Nair SV, Jayakumar R. Cetuximab conjugated O-carboxymethyl chitosan nanoparticles for targeting EGFR overexpressing cancer cells. *Carbohydrate polymers*. 2013;93(2):661-669.
134. Kaluzova M, Bouras A, Machaidze R, Hadjipanayis CG. Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles. *Oncotarget*. 2015;6(11):8788-8806.
135. Sabra R, Billa N, Roberts CJ. Cetuximab-conjugated chitosan-pectinate (modified) composite nanoparticles for targeting colon cancer. *International journal of pharmaceutics*. 2019;572:118775.
136. Kumari L, Ehsan I, Mondal A, Al Hoque A, Mukherjee B, Choudhury P, Sengupta A, Sen R, Ghosh P. Cetuximab-conjugated PLGA nanoparticles as a prospective targeting therapeutics for non-small cell lung cancer. *Journal of drug targeting*. 2023;31(5):521-536.
137. Safaei M, Khosravian P, Kazemi Sheykhshabani S, Mardani G, Elahian F, Mirzaei SA. Enzyme-sensitive nanoparticles, smart TAT and cetuximab conjugated immunoliposomes to overcome multidrug resistance in breast cancer cells. *Toxicology and applied pharmacology*. 2022;441:115989.

138. Duwa R, Banstola A, Emami F, Jeong J-H, Lee S, Yook S. Cetuximab conjugated temozolomide-loaded poly (lactic-co-glycolic acid) nanoparticles for targeted nanomedicine in EGFR overexpressing cancer cells. *Journal of Drug Delivery Science and Technology*. 2020;60:101928.
139. Hein JE, Fokin VV. Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(I) acetylides. *Chemical Society reviews*. 2010;39(4):1302-1315.
140. Khan A, Naaz F, Basit R, Das D, Bisht P, Shaikh M, Lone BA, Pokharel YR, Ahmed QN, Parveen S, Ali I, Singh SK, Chashoo G, Shafi S. 1,2,3-Triazole Tethered Hybrid Capsaicinoids as Antiproliferative Agents Active against Lung Cancer Cells (A549). *ACS Omega*. 2022;7(36):32078-32100.
141. Agalave SG, Maujan SR, Pore VS. Click chemistry: 1,2,3-triazoles as pharmacophores. *Chemistry, an Asian journal*. 2011;6(10):2696-2718.
142. Chen TC, Fonseca CO, Schönthal AH. Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy. *American journal of cancer research*. 2015;5(5):1580-1593.
143. Puppala ER, Jain S, Saha P, Rachamalla M, Np S, Yalamarathi SS, Abubakar M, Chaudhary A, Chamundeswari D, Usn M, Gangasani JK, Naidu VGM. Perillyl alcohol attenuates rheumatoid arthritis via regulating TLR4/NF- $\kappa$ B and Keap1/Nrf2 signaling pathways: A comprehensive study on in vitro and in vivo experimental models. *Phytomedicine*. 2022;97:153926.
144. Andrade Próspero DF, Reis Filho AC, Piauilino CA, Lopes EM, de Sousa DP, de Castro Almeida FR. Effects of isopulegol in acute nociception in mice: Possible involvement of muscarinic receptors, opioid system and l-arginine/NO/cGMP pathway. *Chemico-biological interactions*. 2018;293:55-60.
145. Bamou FZ, Le TM, Tayeb BA, Tahaei SAS, Minorics R, Zupkó I, Szakonyi Z. Antiproliferative Activity of (-)-Isopulegol-based 1,3-Oxazine, 1,3-Thiazine and 2,4-Diaminopyrimidine Derivatives. *ChemistryOpen*. 2022;11(10):e202200169.
146. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of computational chemistry*. 2010;31(2):455-461.
147. Das B, Baidya ATK, Devi B, Rom T, Paul AK, Thakur B, Darreh-Shori T, Kumar R. Synthesis, single crystal X-ray, DFT, spectroscopic, molecular docking studies and in vitro biological evaluation of compound N-benzyl-4-(4-chlorophenyl)-2-oxobutanamide. *Journal of Molecular Structure*. 2023;1276:134782.
148. Khare V, Sakarchi WA, Gupta PN, Curtis ADM, Hoskins C. Synthesis and characterization of TPGS–gemcitabine prodrug micelles for pancreatic cancer therapy. *RSC Advances*. 2016;6(65):60126-60137.
149. Rout SK, Priya V, Vikas, Mehata AK, Muthu MS. Abciximab coated albumin nanoparticles of rutin for improved and targeted antithrombotic effect. *Journal of Drug Delivery Science and Technology*. 2022;76:103785.
150. Tarhini M, Benlyamani I, Hamdani S, Agusti G, Fessi H, Greige-Gerges H, Bentaher A, Elaissari A. Protein-Based Nanoparticle Preparation via Nanoprecipitation Method. *Materials (Basel, Switzerland)*. 2018;11(3).
151. Florkiewicz W, Słota D, Placek A, Pluta K, Tyliszczak B, Douglas TEL, Sobczak-Kupiec A. Synthesis and Characterization of Polymer-Based Coatings Modified with Bioactive Ceramic and Bovine Serum Albumin. *Journal of functional biomaterials*. 2021;12(2).

152. Solanki R, Patel K, Patel S. Bovine Serum Albumin Nanoparticles for the Efficient Delivery of Berberine: Preparation, Characterization and In vitro biological studies. *Colloids and Surfaces A: Physicochemical and Engineering Aspects*. 2021;608:125501.
153. Salim EI, Mosbah AM, Elhussiny FA, Hanafy NAN, Abdou Y. Preparation and characterization of cetuximab-loaded egg serum albumin nanoparticles and their uses as a drug delivery system against Caco-2 colon cancer cells. *Cancer Nanotechnology*. 2023;14(1):4.
154. Chen Z, Chen J, Wu L, Li W, Chen J, Cheng H, Pan J, Cai B. Hyaluronic acid-coated bovine serum albumin nanoparticles loaded with brucine as selective nanovectors for intra-articular injection. *International journal of nanomedicine*. 2013;8:3843-3853.
155. Zhang Y, Zhu X, Chen B. Adhesion force evolution of protein on the surfaces with varied hydration extent: Quantitative determination via atomic force microscopy. *Journal of Colloid and Interface Science*. 2022;608:255-264.
156. Jiang D, Xu M, Pei Y, Huang Y, Chen Y, Ma F, Lu H, Chen J. Core-matched nanoassemblies for targeted co-delivery of chemotherapy and photosensitizer to treat drug-resistant cancer. *Acta biomaterialia*. 2019;88:406-421.
157. Kutty RV, Feng SS. Cetuximab conjugated vitamin E TPGS micelles for targeted delivery of docetaxel for treatment of triple negative breast cancers. *Biomaterials*. 2013;34(38):10160-10171.
158. Kim D, Maharjan P, Jin M, Park T, Maharjan A, Amatya R, Yang J, Min KA, Shin MC. Potential Albumin-Based Antioxidant Nanoformulations for Ocular Protection against Oxidative Stress. *Pharmaceutics*. 2019;11(7).
159. Honary S, Jahanshahi M, Golbayani P, Ebrahimi P, Ghajar K. Doxorubicin-loaded albumin nanoparticles: formulation and characterization. *Journal of nanoscience and nanotechnology*. 2010;10(11):7752-7757.
160. Xiong S, George S, Ji Z, Lin S, Yu H, Damoiseaux R, France B, Ng KW, Loo SC. Size of TiO<sub>2</sub> nanoparticles influences their phototoxicity: an in vitro investigation. *Archives of toxicology*. 2013;87(1):99-109.
161. Priya V, Singh SK, Revand R, Kumar S, Mehata AK, Sushmitha P, Mahto SK, Muthu MS. GPIIb/IIIa Receptor Targeted Rutin Loaded Liposomes for Site-Specific Antithrombotic Effect. *Molecular Pharmaceutics*. 2023;20(1):663-679.
162. Kumbham S, Paul M, Itoo A, Ghosh B, Biswas S. Oleanolic acid-conjugated human serum albumin nanoparticles encapsulating doxorubicin as synergistic combination chemotherapy in oropharyngeal carcinoma and melanoma. *International journal of pharmaceutics*. 2022;614:121479.
163. Vikas, Viswanadh MK, Mehata AK, Sharma V, Priya V, Varshney N, Mahto SK, Muthu MS. Bioadhesive chitosan nanoparticles: Dual targeting and pharmacokinetic aspects for advanced lung cancer treatment. *Carbohydrate polymers*. 2021;274:118617.
164. Abedi Gaballu F, Abbaspour-Ravasjani S, Mansoori B, Yekta R, Hamishehkar H, Mohammadi A, Dehghan G, Shokouhi B, Ghahremani Dehbokri S, Baradaran B. Comparative of in vitro Evaluation between Erlotinib Loaded Nanostructured Lipid Carriers and Liposomes against A549 Lung Cancer Cell Line. *Iranian journal of pharmaceutical research : IJPR*. 2019;18(3):1168-1179.
165. Zhang Y, Chen X, Gueydan C, Han J. Plasma membrane changes during programmed cell deaths. *Cell research*. 2018;28(1):9-21.
166. Atale N, Gupta S, Yadav UC, Rani V. Cell-death assessment by fluorescent and nonfluorescent cytosolic and nuclear staining techniques. *Journal of microscopy*. 2014;255(1):7-19.

167. Dutta D, Paul B, Mukherjee B, Mondal L, Sen S, Chowdhury C, Debnath MC. Nanoencapsulated betulinic acid analogue distinctively improves colorectal carcinoma in vitro and in vivo. *Scientific Reports*. 2019;9(1):11506.
168. Eruslanov E, Kusmartsev S. Identification of ROS using oxidized DCFDA and flow-cytometry. *Methods in molecular biology (Clifton, NJ)*. 2010;594:57-72.
169. Hemlata, Gupta S, Tejavath KK. ROS-Mediated Apoptosis Induced by BSA Nanospheres Encapsulated with Fruit Extract of Cucumis prophetarum in Various Human Cancer Cell Lines. *ACS Omega*. 2021;6(15):10383-10395.
170. Rieger AM, Nelson KL, Konowalchuk JD, Barreda DR. Modified annexin V/propidium iodide apoptosis assay for accurate assessment of cell death. *Journal of visualized experiments : JoVE*. 2011(50).
171. Ramalingam V, Revathidevi S, Shanmuganayagam T, Muthulakshmi L, Rajaram R. Biogenic gold nanoparticles induce cell cycle arrest through oxidative stress and sensitize mitochondrial membranes in A549 lung cancer cells. *RSC Advances*. 2016;6(25):20598-20608.
172. Vikas, Mehata AK, Suseela MNL, Behera C, Kumari P, Mahto SK, Muthu MS. Chitosan-alginate nanoparticles of cabazitaxel: Design, dual-receptor targeting and efficacy in lung cancer model. *International journal of biological macromolecules*. 2022;221:874-890.
173. Jha A, Viswanadh MK, Burande AS, Mehata AK, Poddar S, Yadav K, Mahto SK, Parmar AS, Muthu MS. DNA biodots based targeted theranostic nanomedicine for the imaging and treatment of non-small cell lung cancer. *International journal of biological macromolecules*. 2020;150:413-425.
174. Raes F, Sobilo J, Le Mée M, Rétif S, Natkunarajah S, Lerondel S, Le Pape A. High Resolution Ultrasound and Photoacoustic Imaging of Orthotopic Lung Cancer in Mice: New Perspectives for Onco-Pharmacology. *PloS one*. 2016;11(4):e0153532.
175. Lu W, Zhang Y, Tan YZ, Hu KL, Jiang XG, Fu SK. Cationic albumin-conjugated pegylated nanoparticles as novel drug carrier for brain delivery. *Journal of controlled release : official journal of the Controlled Release Society*. 2005;107(3):428-448.
176. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *Journal of immunological methods*. 1983;65(1-2):55-63.
177. Lee SH, Meng XW, Flatten KS, Loegering DA, Kaufmann SH. Phosphatidylserine exposure during apoptosis reflects bidirectional trafficking between plasma membrane and cytoplasm. *Cell death and differentiation*. 2013;20(1):64-76.
178. Pozarowski P, Darzynkiewicz Z. Analysis of cell cycle by flow cytometry. *Methods in molecular biology (Clifton, NJ)*. 2004;281:301-311.
179. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Advanced drug delivery reviews*. 2016;99(Pt A):28-51.
180. Hoosain FG, Choonara YE, Tomar LK, Kumar P, Tyagi C, du Toit LC, Pillay V. Bypassing P-Glycoprotein Drug Efflux Mechanisms: Possible Applications in Pharmacoresistant Schizophrenia Therapy. *BioMed research international*. 2015;2015:484963.
181. Trott O, Olson AJ. Jvarkit. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of molecular graphics and modeling*. 2010;31(2):455-461.
182. Jithan A, Madhavi K, Madhavi M, Prabhakar K. Preparation and characterization of albumin nanoparticles encapsulating curcumin intended for the treatment of breast cancer. *International journal of pharmaceutical investigation*. 2011;1(2):119-125.


183. Jia X, Hu X, Wang W, Du C. Non-covalent loading of ionic liquid-functionalized nanoparticles for bovine serum albumin: experiments and theoretical analysis. *RSC Adv.* 2019;9(33):19114-19120.
184. Shukla VN, Vikas, Mehata AK, Setia A, Kumari P, Mahto SK, Muthu MS, Mishra SK. EGFR targeted albumin nanoparticles of oleanolic acid: In silico screening of nanocarrier, cytotoxicity and pharmacokinetics for lung cancer therapy. *International journal of biological macromolecules.* 2023;246:125719.
185. Chiu MH, Prenner EJ. Differential scanning calorimetry: An invaluable tool for a detailed thermodynamic characterization of macromolecules and their interactions. *Journal of pharmacy & bioallied sciences.* 2011;3(1):39-59.
186. Vikas, Sahu HK, Mehata AK, Viswanadh MK, Priya V, Muthu MS. Dual-receptor-targeted nanomedicines: emerging trends and advances in lung cancer therapeutics. *Nanomedicine (London, England).* 2022;17(19):1375-1395.
187. Kumar V, Lal K, Naveen, Tittal RK. The fate of heterogeneous catalysis & click chemistry for 1,2,3-triazoles: Nobel prize in chemistry 2022. *Catalysis Communications.* 2023;176:106629.
188. Jiang Y, Chen X, Qu L, Wang J, Yuan J, Chen S, Li X, Qu C. Ultrasonic-assisted synthesis of chrysin derivatives linked with 1,2,3-triazoles by 1,3-dipolar cycloaddition reaction. *Ultrasonics Sonochemistry.* 2011;18(2):527-533.
189. Hou W, Luo Z, Zhang G, Cao D, Li D, Ruan H, Ruan BH, Su L, Xu H. Click chemistry-based synthesis and anticancer activity evaluation of novel C-14 1,2,3-triazole dehydroabiatic acid hybrids. *European Journal of Medicinal Chemistry.* 2017;138:1042-1052.
190. Tao C-Z, Cui X, Li J, Liu A-X, Liu L, Guo Q-X. Copper-catalyzed synthesis of aryl azides and 1-aryl-1,2,3-triazoles from boronic acids. *Tetrahedron Letters.* 2007;48(20):3525-3529.
191. Jaghoori MM, Bleijlevens B, Olabarriaga SD. 1001 Ways to run AutoDock Vina for virtual screening. *Journal of computer-aided molecular design.* 2016;30(3):237-249.
192. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: New Docking Methods, Expanded Force Field, and Python Bindings. *Journal of chemical information and modeling.* 2021;61(8):3891-3898.
193. Jejurikar BL, Rohane SH. *Drug designing in discovery studio.* 2021.
194. Jo S, Kim T, Iyer VG, Im WJ. CHARM-GUI: a web-based graphical user interface for CHARMM. 2008;29(11):1859-1865.
195. Lee J, Cheng X, Swails J, Yeom M, Eastman P, Lemkul J, Wei S, Buckner J, Jeong J, Qi Y, J. C. T. BROOKS, CL, 3RD, MACKERELL, AD, JR., KLAUDA, JB & IM, W. 2016. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field. 12:405-413.
196. Daina A, Michielin O, Zoete VJSr. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. 2017;7(1):42717.



**Chapter 08**  
**List of publications**

## 8 List of publications

1. Shukla VN, Vikas, Mehata AK, Setia A, Kumari P, Mahto SK, Muthu MS, Mishra SK. EGFR targeted albumin nanoparticles of oleanolic acid: *In silico* screening of nanocarrier, cytotoxicity and pharmacokinetics for lung cancer therapy. *Int J Biol Macromol.* 2023 Jul 5; 246:125719. doi: 10.1016/j.ijbiomac.2023.125719. PMID: 37419266. (Impact Factor: 8.2)
2. Vishwa Nath Shukla, Vikas, Abhishesh Kumar Mehata, Aseem Setia, Pooja Kumari, Sanjeev Kumar Mahto, Madaswamy S. Muthu, Sunil Kumar Mishra, Rational design of surface engineered albumin nanoparticles of asiatic acid for EGFR targeted delivery to lung cancer: formulation development and pharmacokinetics, *Colloids and Surfaces A: Physicochemical and Engineering Aspects*, 2023, 132188, ISSN 0927-7757, <https://doi.org/10.1016/j.colsurfa.2023.132188>. (Impact Factor: 5.2)
3. Vishwa Nath Shukla et al, Discovery and biological evaluation of click chemistry inspired triazole derivatives through structural modification of bioactive natural products for the treatment of breast cancer \*.  
(\*manuscript under communication)
4. Vishwa Nath Shukla et al, Synthesis and biological evaluation of natural products (IPG) derived 1,2,3-triazole derivatives for breast cancer therapy \*.  
(\*manuscript under preparation)



**Chapter 09**  
**Curriculum Vitae**

## 9 Curriculum Vitae

### **RESEARCH INTEREST:**

Bioassay-guided isolation and characterization of potential anticancer natural products. Formulation development and targeted delivery of bioactive phytochemicals for the management of cancer. Semi-synthesis of bioactive natural products.

### **ACADEMIC CREDENTIALS**

<b>Course</b>	<b>University / Board</b>	<b>Year of passing</b>	<b>Result</b>
Ph.D.	Indian Institute of Technology (Banaras Hindu University), Varanasi	2016-2023	Ph.D. thesis submitted
M.S. (Pharm.)	National Institute of Pharmaceutical Education and Research (NIPER)	2010	CGPA 9.04/10
B. Pharm	Uttar Pradesh Technical University (UPTU), Lucknow	2008	72.10%

### **RESEARCH EXPERIENCE:**

- a.) Research experience at Organic Synthesis & Process Chemistry Division of CSIR-Indian Institute of Chemical Technology (CSIR-IICT), Hyderabad (India).
- b.) Research experience at Medicinal & Process Chemistry Division of CSIR-Central Drug Research Institute (CSIR-CDRI), Lucknow (India).
- c.) One year M.S. Pharm. project entitled “Bioassay-guided isolation and identification of anti-cancer compound(s) from Indian medicinal plants” at CSIR-Indian Institute of Chemical Biology (CSIR-IICB), Kolkata (India).
- d.) Worked at analytical R&D of Fresenius Kabi Oncology Ltd.